Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children (IPTc/ITNs)

This study has been completed.
Sponsor:
Collaborators:
Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso
Malaria Research and Training Centre, Mali
Information provided by:
London School of Hygiene and Tropical Medicine
ClinicalTrials.gov Identifier:
NCT00738946
First received: August 20, 2008
Last updated: June 3, 2010
Last verified: June 2010
  Purpose

An investigation will be made of the combined impact of insecticide-treated nets and intermittent preventive treatment with amodiaquine + sulfadoxine-pyrimethamine on malaria morbidity in children in Burkina Faso and Mali.Three rounds of treatment will be given during the malaria season in one year and the follow-up will be extended into the second year by passive surveillance.


Condition Intervention
Malaria
Drug: Intermittent preventive treatment with AQ+ SP

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children

Resource links provided by NLM:


Further study details as provided by London School of Hygiene and Tropical Medicine:

Primary Outcome Measures:
  • Incidence of clinical malaria [ Time Frame: 2008-2009 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Incidence of severe malaria, Incidence of anemia, Prevalence of anemia, Prevalence of parasitemia, Proportion of children with parasites carrying resistance markers to AQ and SP, Incidence of hospital admissions due to malaria. [ Time Frame: 2008-2009 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 6000
Study Start Date: August 2008
Study Completion Date: December 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 2
Amodiaquine+pyrimethamine versus placebo
Drug: Intermittent preventive treatment with AQ+ SP
Amodiaquine (10 mg/kg over 3 days) and Sulfadoxine Pyrimethamine (25 mg of sulfadoxine + 1.25 mg of pyrimethamine per kg in a single dose) or placebo administered over 3 rounds of one month interval
Other Name: IPTc

Detailed Description:

The trial will be conducted in 6000 children in Burkina Faso and Mali in 2008 and 2009. Each site will enroll 3,000 children. All children will be allocated a long lasting insecticide-treated net and randomized to receive to treatment (amodiaquine + sulfadoxine-pyrimethamine (AQ+SP)) or placebo (AQ-placebo + SP-placebo. Treatment will be administered over 3 rounds during the high malaria transmission season, with one month interval between rounds. Full course treatment of AQ and SP will be administered on each occasion. Treatment will not be given in the second year. Passive surveillance of malaria will be implemented for the monitoring of malaria morbidity and to assess whether children who received intermittent preventive treatment (IPT) are at increased risk of malaria. Adverse events will be monitored during each round of IPT administration. To assess the effect of IPTc on the prevalence of malaria infection, a random sample of 150 children will be visited every week during the high malaria transmission period. This number will be increased to 300 during the low transmission season, but the survey will be reduced to monthly visits. Baseline prevalence of genetic markers of resistance to SP and AQ will be estimated. A second cross-sectional survey will be conducted at the end of the malaria transmission season to assess the effect of IPT on the prevalence of genetic markers of resistance to SP and AQ, on the prevalence of anaemia and on nutritional indicators.

  Eligibility

Ages Eligible for Study:   3 Months to 59 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Permanent residence in the study area with no intention of leaving during the surveillance period.
  • Obtention of informed consent.

Exclusion Criteria:

  • Temporary residence in the study area.
  • Absence of informed consent.
  • Presence of a severe, chronic illness such as severe malnutrition (Kwashiorkor or marasmus) or AIDS, likely to interfere with evaluation of the trial results.
  • A history of a previous, significant adverse reaction to either of the study drugs.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00738946

Locations
Burkina Faso
Centre National de Recherche et de Formation sur le Paludisme
Ouagadougou, Kadiogo, Burkina Faso, BP 2208
Mali
Malaria Research and Training Centre
Bamako, Mali
Sponsors and Collaborators
London School of Hygiene and Tropical Medicine
Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso
Malaria Research and Training Centre, Mali
Investigators
Study Director: Brian M Greenwood, MD, FRCP London School of Hygiene and Tropical Medicine
  More Information

No publications provided by London School of Hygiene and Tropical Medicine

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Professor Brian Greenwood, London School of Hygiene and Tropical Medicine
ClinicalTrials.gov Identifier: NCT00738946     History of Changes
Obsolete Identifiers: NCT00745979
Other Study ID Numbers: IPTCVP17
Study First Received: August 20, 2008
Last Updated: June 3, 2010
Health Authority: United Kingdom: Research Ethics Committee
Mali: Ministry of Health
Burkina Faso: Ministry of Health

Keywords provided by London School of Hygiene and Tropical Medicine:
Intermittent Preventive treatment
insecticide treated bednets
malaria

Additional relevant MeSH terms:
Malaria
Parasitic Diseases
Protozoan Infections

ClinicalTrials.gov processed this record on November 20, 2014